

The Royal Marsden NHS Foundation Trust
Drug & Therapeutic Committee minutes
23rd July 2019

Present: Consultant Breast and AOS (deputy chair)
Consultant Sarcoma
Deputy Chief Pharmacist (acting)/Drug Resource Manager (secretary)
Chief Pharmacist
Consultant AOS
Consultant Pharmacist
Finance Manger Cancer Services
Consultant Palliative Care Unit
Medicines Information and Palliative care Pharmacist

In attendance:

1. Minutes of the June meeting

a. Minutes – approved.

2. Conflict of Interest

No conflicts raised.

3. NICE Guidance update

1. TA586. Lenalidomide plus dexamethasone in multiple myeloma, 1 year post bortezomib.
 2. TA587. Lenalidomide plus dexamethasone for previously untreated multiple myeloma (when thalidomide is CI/cannot be tolerated.
- Relevant clinical leads made aware of the guidance.

4. One off drug use requests

1. Regorafenib & nivolumab (via compassionate supply) in mCRC. Further review of evidence being undertaken prior to decision being made (x 2 patients).
2. Blu667 (compassionate supply) RET fusion +ve NSCLC.
3. Cetuximab, Encorafenib & Binimetinib in BRAF mutation mCRC.
4. Accelerated AC regimen in adjuvant Breast ca.
5. Osimertinib (via compassionate supply) in EGFR+ve NSCLC.
6. Toptecan (oral) for small cell prostate ca.

Requests 2-6 approved.

5. Compassionate Supply Program approval process. Presented by Pharmacy.

A review of the processes in place in relation to adoption of compassionate supply programs was undertaken by pharmacy and reviewed by the committee. The current process is to be adapted to make more robust and manageable.

Action:

Approved.

6. Enasidenib (via compassionate supply). Presented by the Haematology unit.

Proposal for use monotherapy for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in line with the compassionate supply program inclusion criteria.

Action:

Approved.

7. Polatuzumab (via compassionate supply). Presented by the Haematology unit.

Proposed for use as in adults with relapsed or refractory diffuse large B-cell lymphoma for whom hematopoietic stem cell transplant is not suitable, in line with compassionate supply program criteria.

Action:

Approved.

8. Encorafib, binimetinib cetuximab (via compassionate supply). Presented by Gastro-Intestinal unit.

Proposed for use as in patients with who have BRAFV600E mutant metastatic colorectal cancer and have received 2 prior lines of treatment, in line with compassionate supply program criteria.

Action:

Approved.

9. Accelerated Epirubicin & Cisplatin regimen. Presented by Breast unit

Proposed for use in adjuvant or neo-adjuvant treatment of triple negative early stage breast cancer, or adjuvant or neo-adjuvant high risk ER+ve early stage breast cancer, in selected fit patients.

Action:

Approved.

10. 1% lidocaine infusion- peri-operative intravenous. Presented by Anaesthetics department.

Proposed for use in major abdominal surgery in patients with no contra-indications to lidocaine. There is evidence that perioperative intravenous infusion of lidocaine is associated with earlier return of gut function, reduced postoperative pain scores, reduced opioid consumption and shorter length of hospital stay compared to placebo, in patients undergoing gastrointestinal surgery.

Action:

Approved.

11. Medicines Management Policy. Presented by Pharmacy.

Update to policy.

Action:

Approved.

12. Management of Anti-Platelet and Anti-Thrombotic Therapy Prior to

Insertion of Fiducial Markers for Prostate Image-Guided Radiotherapy (IGRT). Presented by Radiography department.

Update to policy.

Action:

Approved.

13. AOB

Date of the Next Meeting:

Tuesday 25th of June (pm), 15:00 – 17:00

Minutes Approved	DTC chair : Tuesday 24 th September 2019
------------------	---

Date of next meeting 24 th September 2019.
